129 related articles for article (PubMed ID: 6209605)
1. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
[No Abstract] [Full Text] [Related]
2. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
[No Abstract] [Full Text] [Related]
3. [Value of testosterone, FSH and LH on plasma in patients with prostatic adenoma and carcinoma before and after different hormonal treatments].
Garcia de la Peña E; Ramos F; Horcajada C; Cifuentes Delatte L; Vivanco F
Rev Clin Esp; 1978 Jan; 148(1):19-23. PubMed ID: 76325
[No Abstract] [Full Text] [Related]
4. Induction and maintenance of castration by an LHRH analogue: D-Trp6 LHRH or decapeptyl.
Fretin J; Demerle F; Jardin A
Prog Clin Biol Res; 1987; 243A():245-7. PubMed ID: 2958855
[No Abstract] [Full Text] [Related]
5. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
[TBL] [Abstract][Full Text] [Related]
6. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
[TBL] [Abstract][Full Text] [Related]
7. Serum bioactive and immunoreactive follicle stimulating hormone during chronic treatment with gonadotropin releasing hormone agonist in elderly men.
Matzkin H; Braf Z; Dekel N
Horm Metab Res; 1991 Feb; 23(2):76-80. PubMed ID: 1710593
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of prostatic cancers by periodic administration of a delayed-release preparation of D-Trp(6)-LHRH].
Roger M; Duchier J; Lahlou N; Schally AV
Ann Urol (Paris); 1986; 20(2):109-12. PubMed ID: 2424359
[TBL] [Abstract][Full Text] [Related]
9. The use of a potent stimulatory LHRH analog (D-Trp-6, LHRH) in the induction of ovulation.
Canales ES; Montvelinsky H; Fonseca ME; Zárate A; Kastin AJ; Coy DH; Schally AV
Int J Fertil; 1980; 25(3):193-7. PubMed ID: 6108929
[TBL] [Abstract][Full Text] [Related]
10. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
11. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
[TBL] [Abstract][Full Text] [Related]
12. Medical reversible castration with D-Trp-6-LH-RH microcapsules for the treatment of endometriosis. Preliminary results in a series of 51 patients.
Zorn JR; Soubrane O; Siboni O; Papageorgiou G
Contrib Gynecol Obstet; 1987; 16():254-9. PubMed ID: 2961507
[No Abstract] [Full Text] [Related]
13. Prostatic cancer: treatment with long-acting LHRH analogue.
Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
[TBL] [Abstract][Full Text] [Related]
14. [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
Niijima T; Isurugi K; Kawabe K; Kinoshita K; Asano M; Nakauchi K; Fujita K; Nishimura Y; Nitoh H; Yokoyama M
Hinyokika Kiyo; 1988 Jul; 34(7):1297-307. PubMed ID: 2459944
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
[No Abstract] [Full Text] [Related]
16. [Study of the interdependence between prostatic hypertrophy and disorders in hormone levels. Preliminary report. 1. Study of blood testosterone].
Szymanoski J; Baranowska B; Migdalska B; Kozlowicz I
J Urol Nephrol (Paris); 1976; 82(10-11):827-36. PubMed ID: 63569
[TBL] [Abstract][Full Text] [Related]
17. Effect of spironolactone on testosterone and LHRH responsiveness in women with polycystic ovarian disease.
Evron S; Yosef SM; Schenker JG; Diamant YZ
Isr J Med Sci; 1984 Jul; 20(7):630-3. PubMed ID: 6432730
[No Abstract] [Full Text] [Related]
18. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
Wenderoth UK; Jacobi GH
Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
[TBL] [Abstract][Full Text] [Related]
19. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
20. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
Katayama T; Umeda K; Kazama T
Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
